Dr. Jeremy Abramson, Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center and principal investigator of the study discusses the updated efficacy and safety data results for Seagen’s ADCETRIS ® (brentuximab vedotin) in combination with an immunotherapy-containing regimen. These data were presented at the 17th International Conference on Malignant Lymphoma (ICML).
Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.
Dr. Abramson’s clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, as well as Hodgkin lymphoma, and chronic lymphoid leukemias. His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and a Fellow of the American College of Physicians. Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely.